Floatz Rating
BBB76/100
Confidence
Indicative
Sponsor
Novartis
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00673608CT.gov Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload | — | Completed | — | — | — |
NCT00235391CT.gov Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload | — | Completed | — | — | — |
NCT00061763CT.gov Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diamond-Blackfan Anemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Deferasirox (this asset) | Novartis | Approved | BBB · 76 |
| Fludarabine | Fred Hutchinson Cancer Center | P2/3 | BBB |
| Busulfanum | Paul Szabolcs | P2/3 | BBB |
| Cyclophosphamide | Paul Szabolcs | P2/3 | BB |
| Thiotepa | Fred Hutchinson Cancer Center | P2 | BB |
| Alemtuzumab | Paul Szabolcs | P2 | B |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | Masonic Cancer Center, University of Minnesota | P2/3 | B |
| Methotrexate | Fred Hutchinson Cancer Center | P2 | B |
| Tacrolimus | Fred Hutchinson Cancer Center | P2 | B |
+16 more in the Diamond-Blackfan Anemia cohort
Other indications for Deferasirox
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Iron Poisoning | — | P4 | A · 82 |
| Hemosiderosis | — | P4 | A · 81 |
| Beta-Thalassemia Major | — | P4 | BBB · 79 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Deferasirox in Diamond-Blackfan Anemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/deferasirox-diamond-blackfan-anemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →